Probiodrug, a biopharmaceutical company developing treatments for Alzheimer’s disease, says Mark Booth has joined the company as Chief Business Officer and a member of the Management Board. He brings more than 30 years of biopharmaceutical experience to the Halle, Germany based firm.
Most recently he was Chief Commercial Officer at Orexigen Therapeutics, where he also played a leadership role in all business development and investor relations activities.
Prior to Orexigen Therapeutics, Booth was President of Takeda Pharmaceuticals North America (TPNA) and before this, Senior Vice President, General Manager at Immunex.
He also held multiple roles at Abbott Laboratories, moving latterly to Division Vice President, General Manager for the anti-infective franchise.
